Rebelo Mónica, Macedo António J, Nogueira Graça, Trigo Conceição, Kaku Sashicanta
Serviço de Cardiologia Pediátrica, Hospital de Santa Marta, Lisboa, Portugal.
Rev Port Cardiol. 2006 May;25(5):477-81.
Fetal tachycardia is an uncommon condition that if sustained may lead to fetal death. There is no consensus regarding the optimum treatment. The aim of this study was to evaluate the safety and efficacy of sotalol in the treatment of fetal tachycardia.
This was a retrospective study of patients treated for fetal tachycardia with sotalol in a pediatric cardiology department over a ten-year period.
There were eight fetuses treated for supraventricular tachycardia and sotalol was used in six of them. Mean gestational age was 30 weeks. None of them had congenital heart disease; two fetuses had hydrops and one had hydrocephalus. All had supraventricular tachycardia and two had atrial flutter. Drug treatment was successful in establishing sinus rhythm in five of the six fetuses treated with sotalol and no adverse effects were recorded in the mothers. There were no deaths. Supraventricular tachycardia was present in three infants at birth.
In this study sotalol was successful and safe in the treatment of fetal tachycardia, but given the small sample size, more studies are needed to validate this conclusion.
胎儿心动过速是一种罕见的情况，如果持续存在可能导致胎儿死亡。关于最佳治疗方法尚无共识。本研究的目的是评估索他洛尔治疗胎儿心动过速的安全性和有效性。
这是一项对儿科心脏病科在十年期间用索他洛尔治疗胎儿心动过速的患者进行的回顾性研究。
有8例胎儿接受室上性心动过速治疗，其中6例使用了索他洛尔。平均孕周为30周。他们均无先天性心脏病；2例胎儿有水肿，1例有脑积水。所有胎儿均为室上性心动过速，2例有房扑。在用索他洛尔治疗的6例胎儿中，5例药物治疗成功建立了窦性心律，母亲未记录到不良反应。无死亡病例。3例婴儿出生时存在室上性心动过速。
在本研究中，索他洛尔治疗胎儿心动过速成功且安全，但鉴于样本量小，需要更多研究来验证这一结论。
